1-20 of 270 Search Results for

ibd

Sort by
Book
Book
Book Chapter
Series: Nestlé Nutrition Institute Workshop Series
Volume: 79
Published: 10 September 2014
10.1159/000360670
EISBN: 978-3-318-02670-2
... Abstract Although the randomized controlled trial has become the standard for regulatory approval of new drugs and devices in inflammatory bowel disease (IBD), the components of effective trial design and implementation are still evolving. While induction and maintenance of remission...
Book Chapter
Series: Nestlé Nutrition Institute Workshop Series
Volume: 79
Published: 10 September 2014
10.1159/000360676
EISBN: 978-3-318-02670-2
... Abstract Inflammatory bowel disease (IBD) is an abnormal inflammatory response within the gut to a trigger that has yet to be identified. The family history in many patients, especially those with Crohn's disease, suggests a genetic predisposition. It has been hypothesized that the abnormal...
Book Chapter
Series: Nestlé Nutrition Institute Workshop Series
Volume: 79
Published: 10 September 2014
10.1159/000360686
EISBN: 978-3-318-02670-2
... of which have shown a rapid increase in incidence over the past few decades. In some of these diseases, such as inflammatory bowel disease (IBD), the microbiota is dysbiotic with an abnormal community structure and decrease in diversity. If the dysbiotic microbiota plays a role in disease pathogenesis...
Book Chapter
Series: Nestlé Nutrition Institute Workshop Series
Volume: 79
Published: 10 September 2014
10.1159/000360713
EISBN: 978-3-318-02670-2
... Abstract The dysbiosis theory of inflammatory bowel disease (IBD) posits that there is an alteration in the gut microbiome as an important underpinning of disease etiology. It stands to reason then, that administering agents that could impact on the balance of microbes on the gut could...
Book Chapter
Series: Nestlé Nutrition Institute Workshop Series
Volume: 79
Published: 10 September 2014
10.1159/000360715
EISBN: 978-3-318-02670-2
.../refractory Clostridium difficile infection and appears safe in the short term. Uncontrolled reports suggest the possibility of benefit in a select group of IBD patients, but there is quite limited information so far. FMT for IBD raises significant issues and concerns that warrant further systematic...
Book Chapter
Series: Nestlé Nutrition Institute Workshop Series
Volume: 79
Published: 10 September 2014
10.1159/000360720
EISBN: 978-3-318-02670-2
... Abstract Inflammatory bowel diseases (IBD) are chronic progressive diseases. Current therapeutic strategies have not significantly altered the natural history of IBD. In the wake of other chronic diseases, such as rheumatoid arthritis, the goal of therapy has now shifted from mere control...
Book
Book Cover Image
Series: Nestlé Nutrition Institute Workshop Series
Volume: 79
Published: 10 September 2014
10.1159/isbn.978-3-318-02670-2
EISBN: 978-3-318-02670-2
Book Chapter
Series: Frontiers of Gastrointestinal Research
Volume: 34
Published: 09 July 2015
10.1159/000381578
EISBN: 978-3-318-05474-3
...-individual variability in the pharmacokinetics (PK) of TNF antagonists has been observed in inflammatory bowel disease (IBD) patients [ 1 ]. The PK profile of a monoclonal antibody describes the absorption, distribution, metabolization and elimination of a drug and is dependent on drug, patient and disease...
Book Chapter
Series: Frontiers of Gastrointestinal Research
Volume: 34
Published: 09 July 2015
10.1159/000381598
EISBN: 978-3-318-05474-3
...: Inflammatory bowel disease is associated with an increased risk of melanoma: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2014;12:210-218. 13. Targownik LE, Bernstein CN: Infectious and malignant complications of TNF inhibitor therapy in IBD. Am J Gastroenterol 2013;108:1835-1842...
Book Chapter
Series: Frontiers of Gastrointestinal Research
Volume: 34
Published: 09 July 2015
10.1159/000381611
EISBN: 978-3-318-05474-3
... and therapeutic failure in infliximab-to-adalimumab switchers with IBD. Inflamm Bowel Dis 2014;20:1714-1721. 22. Mazor Y, Almog R, Kopylov U, et al: Adalimumab drug and antibody levels as predictors of clinical and laboratory response in patients with Crohn's disease. Aliment Pharmacol Ther 2014;40:620-628. ...
Book Chapter
Published: 22 March 2011
10.1159/000322430
EISBN: 978-3-8055-9673-2
... Abstract Genome-wide association studies have identified over 100 significant inflammatory bowel disease (IBD) associations in European, Asian and African populations. Genetic loci demonstrating disease association observed in multiple populations may highlight particularly essential...
Book Chapter
Published: 22 March 2011
10.1159/000322433
EISBN: 978-3-8055-9673-2
... Abstract Changing trends in the epidemiology of inflammatory bowel disease (IBD) provide an opportunity to examine possible etiological hypotheses. Why did IBD emerge in developed nations in the middle of the 20th century; and why did it emerge initially as ulcerative colitis (UC) but now...
Book Chapter
Series: Nestlé Nutrition Institute Workshop Series
Volume: 66
Published: 22 July 2010
10.1159/000318948
EISBN: 978-3-8055-9455-4
..., focusing also on epigenetic imprinting. Introducing Remarks At the reference center for disease prevention, year 2039 somewhere in Europe: The parents, both suffering from inflammatory bowel disease (IBD), bring their two healthy children (2 and 5 years old) in your office and ask for advice how...
Book Chapter
Series: World Review of Nutrition and Dietetics
Volume: 124
Published: 15 June 2022
10.1159/000516710
EISBN: 978-3-318-06296-0
... bowel disease (IBD) is a heterogeneous group of chronic and relapsing inflammatory conditions of the gastrointestinal tract. The two main entities of IBD are Crohn’s disease (CD) and ulcerative colitis (UC). The peak onset of IBD occurs between 20 and 40 years of age, but every fourth patient...
Book Chapter
Series: Frontiers of Gastrointestinal Research
Volume: 34
Published: 09 July 2015
10.1159/000381607
EISBN: 978-3-318-05474-3
... Abstract The introduction of biological tumor necrosis factor (TNF)-α inhibitors has transformed the paradigm for the treatment of inflammatory bowel disease (IBD), i.e. Crohn's disease and ulcerative colitis. The specific TNF inhibitors currently approved for patients with IBD are infliximab...
Book Chapter
Series: Nestlé Nutrition Institute Workshop Series
Volume: 79
Published: 10 September 2014
10.1159/000360721
EISBN: 978-3-318-02670-2
... This 79th Nestlé Nutrition Institute Workshop was dedicated to various aspects of inflammatory bowel diseases (IBD) focusing on nutrition, gut microbiota and immunity as potential therapeutic targets for IBD. During this 1.5-day meeting, 15 expert presentations with extensive panel discussions...
Book Chapter
Series: Nestlé Nutrition Institute Workshop Series
Volume: 79
Published: 10 September 2014
10.1159/000360664
EISBN: 978-3-318-02670-2
... Abstract Inflammatory bowel disease (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), are chronic debilitating diseases that occur in populations around the world. The underlying etiology is thought to be multifactorial. There is a well-defined genetic contribution...
Book Chapter
Series: Frontiers of Gastrointestinal Research
Volume: 34
Published: 09 July 2015
10.1159/000381595
EISBN: 978-3-318-05474-3
... ≥50 years is associated with significantly increased rates of serious infections; therefore, physicians should pay careful attention to detect the development of infections in elderly patients treated with this therapy. Patients with inflammatory bowel disease (IBD) should be considered for the five...